AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Radiopharm shares surge 15.81% premarket after approval to initiate Phase 1 trial of RAD 402 in prostate cancer.
ByAinvest
Friday, Nov 21, 2025 9:09 am ET1min read
Radiopharm Theranostics (RADX) surged 15.81% in premarket trading following the announcement that it received approval to initiate a Phase 1 therapeutic trial of RAD 402 (KLK3-mAb with Tb161) in advanced prostate cancer. This regulatory milestone, reported by GlobeNewswire three days prior, marks a critical step in the development of the company’s targeted radiopharmaceutical candidate, signaling progress in its oncology pipeline and enhancing investor confidence in its therapeutic innovation potential. The approval aligns with the company’s focus on advancing precision medicine for cancer treatment, reinforcing optimism about future clinical and commercial opportunities.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet